Squamous Cell Carcinoma of Head and Neck Clinical Trials in Boston, Massachusetts

8 studies are recruiting for squamous cell carcinoma of head and neck in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

   The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   56 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06385080 on ClinicalTrials.gov

2. A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

   This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a t…

   Stage

   Phase 1

   Ages

   18 to 74

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   19 in total

   Run by

   Johnson & Johnson Enterprise Innovation Inc.

   See if you can join NCT07219212 on ClinicalTrials.gov

3. A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

   The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   201 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07276399 on ClinicalTrials.gov

4. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

   This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   158 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04389632 on ClinicalTrials.gov

5. Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

   This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: -- implantable microdevice

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT05553782 on ClinicalTrials.gov

6. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

   The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber/Partners Cancer Care Inc, Boston, Massachusetts

   Locations

   20 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT04429542 on ClinicalTrials.gov

7. Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

   This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts Eye and Ear, Boston, Massachusetts

   Run by

   Massachusetts Eye and Ear Infirmary

   See if you can join NCT06744296 on ClinicalTrials.gov

8. Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

   This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indicat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   15 in total

   Run by

   IO Biotech

   See if you can join NCT05280314 on ClinicalTrials.gov